FEATURE STORY
● Bluebird bio and Novo Nordisk enter into research agreement to develop in vivo genome editing candidates
CLINICAL TRIALS – DATAS
● Risdiplam Spinal Muscular Atrophy data demonstrating continued benefit
● ProQR announces positive top-line results from the phase 1/2 study of Sepofarsen in LCA10 patients
● Ionis’ Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
M&A – AGREEMENTS
● Akcea and Pfizer announce licensing agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
● Editas Medicine and MaxCyte announce clinical and commercial license agreement for engineered cell medicines
● PTC Therapeutics establishes strategic collaboration with Aldevron to support GMP plasmid manufacturing
● Lonza agrees to manufacture Prevail Therapeutics’ novel AAV-based gene therapies for patients with neurodegenerative diseases
● Cellectis and Lonza enter cGMP manufacturing service agreement for Cellectis’ allogeneic UCART product candidates
● Alexion and Stealth announce agreement for option to co-develop and commercialize late-stage therapy for mitochondrial diseases
● TrakCel announces strategic partnership with WuXi AppTec Advanced Therapies for optimization of supply chain for cell and gene therapy treatments
To read the full articles: Trend Chart on Innovative Bioindustries October 12th
COMMENTS ARE OFF THIS POST